Positive clinical results for immunotherapy in metastatic/recurrent cervical cancer
Results from two studies shows promise for combination immunotherapy in a population with a high unmet need for new treatments
LAG3 inhibitors are changing the landscape of immunotherapy
After impressive results were achieved in melanoma, there is now great interest in exploring the potential of dual LAG3/PD-1 inhibition in other tumour types
Immune checkpoint inhibition disappoints in relapsed platinum-sensitive ovarian cancer
Addition of the PD-L1 inhibitor atezolizumab to chemotherapy plus bevacizumab showed little or no benefit in the relapsed setting, echoing previous data from front-line therapy
What is the state of play for molecular profiling in gynaecological malignancies?
Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers
Is molecular profiling for gynaecological cancers worth the cost?
In this era of precision medicine, affordable profiling is essential
Is molecular profiling useful in the management of breast cancer?
The value of genomic testing is being increasingly demonstrated and will evolve over time
Encouraging safety data for the use of durvalumab after sequential chemotherapy in stage III unresectable NSCLC
Findings from the PACIFIC-6 trial echo the benefits seen with durvalumab after concomitant chemoradiotherapy, representing a potential alternative for vulnerable and older patients
Atezolizumab shows little heterogeneity in efficacy in high PD-L1 expressers with stage II–IIIA NSCLC
Results from the subgroup analysis of the IMpower010 study also report some patterns of relapse that are in contrast with previously presented findings
Encouraging results with savolitinib in NSCLC with MET exon14 skipping mutations
Overall survival data are in line with those from other MET tyrosine kinase inhibitors and show promise in a tumour subtype with poor prognosis
How long should we give immunotherapy for?
The length of immunotherapy course for metastatic lung cancer was arbitrarily set at 2 years in clinical trials, but definitive studies investigating the optimum duration against the risk-benefit profile are lacking